Clinical trials of the QazCovid-in vaccine against coronavirus infection developed at the Research Institute of Biological Safety Problems of the Committee of Science MES RK have begun.
The Ministry of Health of Kazakhstan, after a thorough check of the documents, issued a permit to conduct phase I/II clinical trials of the Kazakh vaccine QazCovid-in® .
“Within the first and second phases, vaccination of volunteers will be carried out. The World Health Organization has given permission for this. Despite the fact that only 244 people can become volunteers, the RIBSP received a large number of applications from those wishing to participate in clinical trials in a short time. We had to stop accepting applications a few days after the announcement was released. We are grateful to our fellow citizens for such support and trust in our science,” – said Vice Minister of Education and Science of Kazakhstan Miras Daulenov.
Healthy adult volunteers aged 18 to 50 years take part in clinical trials of the vaccine. In phase I of the study, that determines the safety of the vaccine, 44 volunteers who have not had coronavirus and do not have antibodies take part. In the second phase, aimed at the study of immunogenicity, 200 volunteers are planned to participate.
By the way, RIBSP received 688 applications from citizens wishing to participate in clinical trials from all regions of Kazakhstan. They will be screened, and a range of volunteers will be formed for vaccination.
Clinical trials will be conducted at an accredited clinical base – RSE “National Scientific Center of Phthisiopulmonology” of the Ministry of Health of the RK and a certified base according to the GCP standard – “Sentre for Clinical Medicine and Research” LLP.
Remind you that on July 26, 2020, the QazCovid-in vaccine were first received by seven, then twenty more development scientists led by the Director-General of RIBSP K.D. Zakarya. They developed a growing immunity, the results of the tests showed the safety and high immunogenicity of the vaccine. Today, all employees feel well and continue to work.
As already reported, on May 15, 2020, the World Health Organization (WHO) included Kazakhstan’s inactivated coronavirus vaccine in the list of candidate vaccines, and on August 29 – among those approved for clinical trials.